U.S. Markets close in 1 hr 9 mins
  • S&P 500

    -117.32 (-2.65%)
  • Dow 30

    -895.27 (-2.59%)
  • Nasdaq

    -478.27 (-3.18%)
  • Russell 2000

    -78.54 (-3.51%)
  • Crude Oil

    -1.55 (-2.15%)
  • Gold

    +12.00 (+0.69%)
  • Silver

    -0.14 (-0.63%)

    -0.0001 (-0.0117%)
  • 10-Yr Bond

    -0.0640 (-4.67%)
  • Vix

    +7.38 (+35.46%)

    -0.0082 (-0.5967%)

    -0.5500 (-0.5005%)

    -3,435.44 (-7.15%)
  • CMC Crypto 200

    -48.68 (-4.29%)
  • FTSE 100

    -59.73 (-0.86%)
  • Nikkei 225

    +176.75 (+0.58%)

Daré Bioscience Rallies On FDA Designation For Bacterial Vaginosis Drug

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of the thinly-traded, nano-cap penny stock Daré Bioscience Inc (NASDAQ: DARE) were trading higher Monday.

What Happened

Daré, which focuses on women's health, said Monday that its BV1 — a thermosetting hydrogel containing clindamycin phosphate 2% — has been given the Qualified Infectious Disease Product, or QIDP, designation by the FDA for the treatment of bacterial vaginosis in women.

BVI is a viscous liquid which goes through solution-to-gel transition using the body temperature as a trigger, which facilitates easy direction of the product to the site of infection.

"Receiving QIDP designation for DARE-BV1 for the treatment of BV is validation that BV is a serious infection for which current treatment options are inadequate," Daré CEO Sabrina Martucci Johnson said in a statement.

Why It's Important

The clinical cure rates for currently approved products in bacterial vaginosis are about 37-39%, and the condition affects over 21 million among women ages 14-49, according to Daré.

The proof-of-concept study of BV1 showed an 86% clinical cure rate in the evaluable subjects at the test-of-cure visit after a single administration.

The QIDP designation is meant to incentivize development of antibacterial and antifungal drug products that treat serious or life-threatening infections.

The designation confers:

  • a five-year exclusivity extension, added to any exclusivity for which a QIDP qualifies upon FDA approval

  • The QIDP designation also makes the product candidate eligible for Fast Track designation and Priority Review

What's Next

Daré said it plans to start a late-stage study of BVI in about 250 women in the fourth quarter of 2019.

The company said it believes the Phase 3 study, if successful, would be sufficient for approval of BV1 to treat bacterial vaginosis.

Daré shares were rising 2.67% to 77 cents at the time of publication Monday.

Related Links:

The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.